Evidence from Outcomes: Gender-Neutral 2vHPV Vaccination at Moderate Coverage Drives Rapid Depletion of HPV16/18 Among Vaccinated and Unvaccinated Women
Viruses · 2026
DOI: 10.3390/v18010099 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, 2026. Verfasst von Matti Lehtinen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cervical Cancer Elimination, Karolinska Institutet, 171 77 Stockholm, Sweden. Hauptthemen laut MEDLINE: Human papillomavirus 16, Human papillomavirus 18, Papillomavirus Infections, Papillomavirus Vaccines. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 (RISC), Horizon (RISC), European Union’s Horizon 2020 research and innovation program.
Abstract (Originalsprache)
Human papillomavirus (HPV) vaccination may eventually eradicate oncogenic vaccine-targeted HPVs but only with a strategy that also protects unvaccinated individuals. We compared the impact of gender-neutral and girls-only vaccination strategies on the indirect and direct protection of unvaccinated and vaccinated young women against HPV16/18 infection using HPV16/18 seropositivity and PCR positivity 3–7 years post vaccination as the outcome measure. A total of 33 Finnish communities were randomized to one of three vaccination strategies: bivalent gender-neutral HPV vaccination (Arm A), girls-only HPV vaccination (Arm B), or control hepatitis B vaccination (Arm C). All individuals born between 1992 and 1995 and residing in these communities (n = 80,272) were invited to participate. Overall, 11,662 males and 20,513 females consented, corresponding to vaccination coverages of 25% and 45%, respectively, in 2007–2009. Between 2010 and 2014, 11,396 cervical samples were collected from 18-year-old participants and subjected to high-throughput PCR-based HPV genotyping. In addition, serum samples were obtained from 8022 unvaccinated women under 23 years of age residing in Arm A (n = 2657), Arm B (n = 2691), or Arm C (n = 2674) communities during the pre-vaccination (2005–2010) and post-vaccination (2011–2016) periods. To assess indirect vaccine effects using PCR and serological outcomes in unvaccinated women, we compared reductions in HPV16/18 prevalence from baseline within the gender-neutral and girls-only vaccination arms, using the control arm as a reference. A significant decrease in seroprevalence between the pre- and post-vaccination periods was detected in the gender-neutral communities for both HPV16 (seroprevalence ratio = 0.64) and HPV18 (0.72), whereas no comparable reductions were observed in the girls-only or control communities. In contrast, a significant reduction in HPV18 PCR-based prevalence from baseline to the post-vaccination period was observed in both the gender-neutral (0.32) and girls-only (0.61) communities. However, after accounting for ratios of seroprevalence rations for secular trends, the corresponding decrease in HPV18 seroprevalence was no longer statistically significant. Vaccine efficacy (VE) in Arm A or Arm B versus Arm C of vaccinated women measured the direct protection of vaccinated women by vaccination strategy. HPV16/18 VEs varied between 89% and 96% with some indication of herd effect against HPV18. Robust effectiveness of vaccination against PCR-confirmed cervical HPV16/18 infections, along with rapid indirect protection against HPV16/18 and HPV18 infections, was evident even with vaccination reaching only 25% and 45% coverage. Our results suggest that vaccine efficacy and herd effect induced by gender-neutral 2vHPV vaccination sets the stage for comprehensive HPV eradication, including the unvaccinated in the vaccinated communities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cervical Cancer Elimination, Karolinska Institutet, 171 77 Stockholm, Sweden.
- Finnish Institute of Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland.
- Biobank Borealis of Northern Finland, University of Oulu, P.O. Box 8000, FI-90014 Oulu, Finland.
- Unit of Population Health, University of Oulu, P.O. Box 8000, FI-90014 Oulu, Finland.
- Faculty of Medicine, Tampere University, FI-33014 Tampere, Finland.
- Department of Laboratory Medicine, Clinical Microbiology, Skåne University Hospital Lund, Lund University, Box 117, 221 00 Lund, Sweden.
ORCID-Profile: Ville N Pimenoff, Heljä-Marja Surcel, Joakim Dillner
Förderung
- Horizon 2020 (RISC)
- Horizon (RISC)
- European Union’s Horizon 2020 research and innovation program
- Cancer Foundation Finland
- Karolinska Institutet Funds
Zitieren
APA
Lehtinen, M., Pimenoff, V. N., Eriksson, T., Lagheden, C., Söderlund-Strand, A., Surcel, H. M., & Dillner, J. (2026). Evidence from Outcomes: Gender-Neutral 2vHPV Vaccination at Moderate Coverage Drives Rapid Depletion of HPV16/18 Among Vaccinated and Unvaccinated Women. Viruses. https://doi.org/10.3390/v18010099
Vancouver
Lehtinen M, Pimenoff VN, Eriksson T, Lagheden C, Söderlund-Strand A, Surcel HM, et al. Evidence from Outcomes: Gender-Neutral 2vHPV Vaccination at Moderate Coverage Drives Rapid Depletion of HPV16/18 Among Vaccinated and Unvaccinated Women. Viruses. 2026. doi:10.3390/v18010099
BibTeX
@article{Lehtinen2026,
author = {Lehtinen, Matti and Pimenoff, Ville N and Eriksson, Tiina and Lagheden, Camilla and Söderlund-Strand, Anna and Surcel, Heljä-Marja and Dillner, Joakim},
title = {Evidence from Outcomes: Gender-Neutral 2vHPV Vaccination at Moderate Coverage Drives Rapid Depletion of HPV16/18 Among Vaccinated and Unvaccinated Women},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18010099}
}
EUVIMED